Cancer pain is an important challenge in treatment and requires a rapid onset of action for
its control. In particular, breakthrough cancer pain (BTcP) should be adequately controlled …

Background Oromucosal fentanyl is currently used for the treatment of breakthrough pain
(BTP) in opioid-treated cancer patients. Ethypharm developed a sublingual formulation of …

Background Breakthrough cancer pain (BTCP) is common among cancer patients and
markedly lowers their quality of life. The treatment for BTCP episodes that is recommended …

Despite relative stable and adequately controlled background pain, Breakthrough Cancer
Pain (BTcP) is a transient exarcebation of pain that occurs either spontaneously or in …

Abstract Introduction Breakthrough cancer pain (BTcP) is recognized as a clinically
significant complication of chronic cancer pain with most BTcP episodes peaking in intensity …

ABSTRACT Introduction: Breakthrough cancer pain (BTcP) is an episode of severe intensity
in patients receiving an adequate treatment with opioids able to provide at least mild …

Fentanyl is a lipophilic, short-acting, synthetic opioid with a piperidine chemical structure.
Fentanyl is an effective analgesic for cancer pain, and newer formulations such as the …

Context Fentanyl products have shown superiority to oral opioids for the management of
breakthrough cancer pain (BTcP). However, these studies did not use appropriate patient …

Overview Cancer pain presents a significant clinical challenge. Even when background pain
is effectively controlled, patients often experience episodes of breakthrough cancer pain …

Background and objectives: Breakthrough cancer pain (BTcP) represents an important
clinical challenge in the care of patients with cancer. This trial evaluated the efficacy and …